![Robert Alexander](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Robert Alexander
Plus aucun poste en cours
Profil
Le Dr Robert Alexander est directeur général et administrateur d'Allakos, Inc. et administrateur indépendant d'Allena Pharmaceuticals, Inc. Il est membre du conseil d'administration d'Allakos, Inc. et d'Allena Pharmaceuticals, Inc. Le Dr Alexander a été précédemment employé en tant que directeur général et directeur par ZS Pharma, Inc. et directeur indépendant par Lumena Pharmaceuticals, Inc. et associé directeur par TL Ventures LP, directeur par Genentech, Inc. et directeur par MPM BioEquities Adviser LLC, directeur par MPM Capital Inc. et président exécutif et directeur général par SARcode Bioscience, Inc. Il a également siégé au conseil d'administration d'Alta Partners Management Corp. et de Sonexa Therapeutics, Inc. Il a obtenu son diplôme de premier cycle à l'université de Miami et un doctorat à l'université de Caroline du Nord à Asheville.
Dernières actualités sur Robert Alexander
Anciens postes connus de Robert Alexander
| Sociétés | Poste | Fin |
|---|---|---|
| ALLAKOS INC. | Directeur Général | 15/05/2025 |
| ALLENA PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 01/02/2022 |
| ZS PHARMA INC | Directeur Général | 01/03/2017 |
SARcode Bioscience, Inc.
 SARcode Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Directeur Général | 01/04/2013 |
Alta Partners Management Co. LP
 Alta Partners Management Co. LP Investment ManagersFinance Alta Partners invests in companies located in the United States. The firm focuses on life sciences and healthcare technology services sectors. It participates in seed, early and later stage capital transactions. It acts as the lead investor and takes a seat on board of directors. | Directeur/Membre du Conseil | 01/03/2013 |
Formation de Robert Alexander
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
70
Relations au 1er degré
13
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Alta Partners Management Co. LP
Alta Partners Management Co. LP Investment ManagersFinance Alta Partners invests in companies located in the United States. The firm focuses on life sciences and healthcare technology services sectors. It participates in seed, early and later stage capital transactions. It acts as the lead investor and takes a seat on board of directors. | Finance |
MPM BioEquities Adviser LLC
 MPM BioEquities Adviser LLC Investment ManagersFinance MPM BioEquities Adviser focuses exclusively on global life sciences investments. The firm invests in biotechnology, specialty pharmaceuticals, medical technology and related companies that provide innovative medical products and services to the healthcare industry. They invest across all geographies, stages of development and therapeutic areas. MPM focuses on inflection points in the development of companies, such as the achievement of clinical proof-of-concept data and the achievement of early commercial success, and on reinvigorating commercial platforms with potentially high growth assets. MPM BioVentures I (BB BioVentures, MPM BioVentures Parallel Fund) is a family of funds that was launched in 1997 and is no fully committed with 75% of its investments in biotechnology and 25% in medical devices and other healthcare related fields. The MPM BioVentures I portfolio consists of 26 companies with investments ranging from $5 million to $20 million per company. Within the biotechnology sector, the funds' investments are split between companies focused on therapeutics and enabling technologies. About 80% of the funds' assets are invested in US companies and 20% in European companies. The MPM BioVentures II family of funds closed in the first quarter of 2000. The funds consist of investments in biotechnology, medical devices and other healthcare related fields. The MPM BioVentures II has invested in 35 companies, with investments ranging from $10 million to $50 million. The fund has invested across the entire spectrum of company development, from start-up through mezzanine and PIPES. 85% of the funds' investments are in US companies and 15% are in European and Asian companies. The MPM BioVentures III Fund closed in December of 2002. The fund holds a portfolio of 39 companies, 85% of which are focused on biotechnology and pharmaceutical products and 15% are focused on medical devices and life science tools. The fund's balanced portfolio of early-, mid- and late-stage companies includes investments in public companies through PIPE transactions. The MPM BioVentures IV family of funds was launched in the second quarter of 2006. The funds hold a portfolio of 18 companies with investments ranging from $5 million to $36 million. About 75% of the funds' investments focus on biotechnology and pharmaceutical products and 25% focus on medical device companies. About 25% of the funds' investments have been made outside the US, including investments in Asia and Europe. The MPM BioVentures IV family of funds serves as the lead investor in a majority of its investments and takes an active role as a board member on its portfolio companies' boards of directors. | Finance |
SARcode Bioscience, Inc.
SARcode Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Health Technology |
ZS Pharma, Inc.
 ZS Pharma, Inc. BiotechnologyHealth Technology Develops develop new treatments of kidney and liver diseases | Health Technology |
Lumena Pharmaceuticals, Inc.
 Lumena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops oral therapeutics for rare liver diseases | Health Technology |
TL Ventures LP | |
MPM BioImpact LLC
 MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions. | Finance |
Miami University
 Miami University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sonexa Therapeutics, Inc.
 Sonexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drug treatments for Alzheimer's disease and related disorders | Health Technology |
The University of North Carolina at Asheville
 The University of North Carolina at Asheville Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Allena Pharmaceuticals, Inc.
 Allena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and retails drugs through online | Health Technology |
Allakos, Inc.
 Allakos, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biotechnology company that develops innovative therapeutics which target immunomodulatory receptors for the treatment of allergic, inflammatory and proliferative diseases | Health Technology |
